| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| (loss) income before income taxes | -35,091 | -19,959 | -30,478 | 10,760 |
| Income tax (benefit) expense | -161 | 27 | 119 | 88 |
| Net (loss) income | -34,930 | -19,986 | -30,597 | 10,672 |
| Net income allocated to participating securities | 0 | - | - | 1,287 |
| Net (loss) income available to common stockholders | -34,930 | - | - | 9,385 |
| Net (loss) income per share, basic (in dollars per share) | -0.11 | -0.08 | -0.14 | 0.05 |
| Net (loss) income per share, diluted (in dollars per share) | -0.11 | -0.08 | -0.14 | 0.04 |
| Shares used in computing diluted net (loss) income per share (in shares) | 304,268,000 | 256,950,000 | 220,269,000 | 214,325,000 |
| Weighted average number of common shares outstanding - basic (in shares) | 304,268,000 | 256,950,000 | 220,269,000 | 208,345,000 |
SANGAMO THERAPEUTICS, INC (SGMO)
SANGAMO THERAPEUTICS, INC (SGMO)